StonvexLoading…
StonvexStonvexStonvexCore line items from URGN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $50.96M | $109.79M | $71.95M | $44.47M |
Operating Income | $-20.26M | $-124.86M | $-105.75M | $-78.36M |
Net Income | $-23.57M | $-153.49M | $-127.13M | $-93.78M |
EPS (Diluted) | $-0.47 | $-3.19 | $-2.66 | $-1.97 |
Total Assets | $253.69M | $200.46M | $185.05M | $208.72M |
Total Liabilities | $377.94M | $305.93M | $300.45M | $302.09M |
Cash & Equivalents | $109.97M | $110.75M | $90.04M | $92.90M |
Free Cash Flow OCF − CapEx | $-45.37M | $-162.73M | $-124.39M | $-82.03M |
Shares Outstanding | 48.71M | 48.35M | 46.78M | 46.20M |